De novo donor-specific antibodies (dnDSAs) have been associated with reduced graft survival. Tacrolimus (TAC)-based regimens are the most common among immunosuppressive approaches used in in clinical practice today, yet an optimal therapeutic dose to prevent dnDSAs has not been established. We evaluated mean TAC C 0 (tacrolimus trough concentration) and TAC time in therapeutic range for the risk of dnDSAs in a cohort of 538 patients in the first year after kidney transplantation. A mean TAC C 0 < 8 ng/mL was associated with dnDSAs by 6 months (odds ratio [OR] 2.51, 95%
of TAC dosing and immunologic risk, despite the potential relevance of the latter to intermediate and long-term graft survival. 14, 15 In addition to a narrow and poorly defined therapeutic window, TAC dosing is complicated by significant inter-and intrapatient variability that can be influenced by a range of factors, including genetics, 16 demographics, 17 and drug-drug interactions, 18 ultimately having potentially important implications for adverse outcomes.
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Despite these challenges (or as a result), there is no consensus on how to effectively monitor TAC within the therapeutic window established by each center, 23 even though considerable resources are often allocated to TAC monitoring and management. Warfarin therapy also has a narrow therapeutic window and displays a high degree of dosing variability. 24 Time in therapeutic range (TTR), which calculates the percentage of time a patient is within a predefined target range, has emerged as the standard to assess effective warfarin management in both clinical and research settings. 25, 26 Many of the advantages of this method for drug monitoring may be particularly useful for managing TAC therapy.
This study describes the role of one of our most important immunosuppression drugs in preventing dnDSAs in consecutive kidney and kidney/pancreas transplants placed on triple immunosuppression therapy at a single center. We evaluate the relationship between overall TAC exposure and the risk of dnDSA by analyzing mean TAC trough concentrations (TAC C 0 ) in patients during the first year of kidney transplantation. This risk is placed into the context of a novel and clinically relevant method of drug monitoring, exploring TAC time in TTR and its association with dnDSA development, acute rejection, and death-censored graft loss.
| MATERIALS AND METHODS

| Patient population
This retrospective analysis included all adult patients (≥18 years 
| Immunosuppression
Induction therapy with rabbit anti-thymocyte globulin (rATG, thy- and 10:00 a.m. per our clinic or inpatient protocols. Any TAC level that was undetectable was considered as 0.0 ng/mL and all TAC levels that were < 2 ng/mL or exceeding 15 ng/mL were individually chart reviewed and excluded if they were not valid troughs. Target TAC trough concentrations were 6-9 ng/mL for months 0-3 and 5-8 ng/ mL for months 4-12.
| Time in therapeutic range
The Rosendaal or linear interpolation method was used to calculate time in therapeutic range. Specific details regarding this calculation have been published elsewhere. 27 Briefly, this method assumes that a linear relationship exists between each measured value and then assigns a specific value for each day between tests. We applied the Rosendaal method to calculate TAC TTR using a therapeutic range of 5-10 ng/mL in the first of year of transplantation. TTR <60% or <75% was chosen as high risk based on existing studies applying TTR to warfarin therapy. 
| Clinical outcomes
Acute rejection (AR) included T cell-mediated rejection and ABMR and was diagnosed pathologically in accordance with Banff 2013 criteria in most cases. 28 A minority of patients had a clinical diagnosis of T cell-mediated rejection without histology, defined as the following: (1) acute kidney injury in the absence of other causes, (2) a response to high-dose corticosteroid (500 mg daily for 3-5 days) and/ or rATG 1.5 mg/kg/d for 5-7 days with reduction in serum creatinine to baseline, and (3) negative DSA screening. ABMR and mixed acute humoral/cellular rejection were treated with plasmapheresis, intravenous Ig (IVIg), and rituximab with or without concurrent thymoglobulin as indicated. C4d was detected using immunohistochemistry.
Graft failure was defined as a return to hemodialysis dependence or re-transplantation.
| Statistical methods
Patient characteristics in Table 1 were compared by DSA status using exact chi-square and 2-sample t-tests. Kaplan-Meier probabilities of dnDSA, acute rejection, and death-censored graft survival were plotted and compared by TAC levels using log rank tests.
As a sensitivity analysis, an interval censored nonparametric estimate of time to DSA was calculated, given the assessment times of dnDSA at 1, 6, and 12 months posttransplantation. The standard error for these estimates was calculated using multiple imputation within PROC ICLIFETEST in SAS. Cox's proportional hazards regression model was used to obtain estimates of hazard ratios for acute extracted from the United Network for Organ Sharing (UNOS) database for our center, and then local data were supplemented to provide greater detail. All analysis was performed using SAS v9.4
(SAS Inc., Cary, NC).
| RESULTS
| Demographics and baseline characteristics
There were 538 kidney and kidney-pancreas recipients who met criteria for the analysis. Baseline characteristics for all patients are shown in Table 1 
| Tacrolimus
There were 11 448 trough levels within the first 12 months posttransplantation that were analyzed. Overall median number of TAC Acute rejection included clinically apparent T cell-mediated rejection, antibody-mediated rejection, and mixed.
F I G U R E 2 Kaplan-Meier plot for mean TAC C 0 ranges (ng/mL) and (A) percent dnDSA-free survival by 12 months, (B) percent acute rejection-free survival by 12 months, and (C) percent death-censored graft loss by 5 years (P < .001). A mean TAC C 0 <9 ng/ml compared to ≥9 was not associated with dnDSA at 6 months (OR 2.35, 95% confidence interval
[CI] 0.79-6.93, P = .123) or 12 months (OR 1.96, 95% CI 0.77-5.02, P = .160). Three hundred eighty-one (70.8%) and 409 (76.0%) patients had a mean TAC C 0 <8 ng/mL at 6 months and 12 months, respectively. A mean TAC C 0 < 8 ng/mL compared to ≥8 ng/mL within the first 6 months posttransplantation was associated with dnDSAs by 6 months (OR 2.51, 95% CI 1.32-4.79, P = .005) and a mean TAC C 0 of <8 ng/mL by 12 months was associated with dnDSA by 12 months (OR 2.32, 95% CI 1.30-4.15, P = .004). There was a graded increase in risk of dnDSA by 6 months, with successively lower mean TAC levels. Figure 1 shows dnDSA risk associated with mean TAC C 0 at cut-points between 3 and 9 ng/mL for 6 months and 12 months, adjusted for other covariates.
Ranges for mean TAC C 0 were also analyzed and compared to mean TAC C 0 ≥8 ng/mL for DSA within 12 months (Table 2) . Three hundred eight patients (57.2%) had a mean TAC C 0 within the range of 6-7.9 ng/ mL, and in multivariable analysis, these patients had an increased risk of dnDSA (OR 1.86, 95% CI 1.02-3.39, P = .044). TAC C 0 ranges of 4-5.9 ng/mL (OR 4.44, 95% CI 2.14-9.20, P < .001) and 0-3.9 (OR 5.87, 95% CI 1.42-24.30, P = .015) were associated with an approximately 4.5-fold and 6-fold risk of dnDSA, respectively, when compared to mean TAC C 0 ≥8 ng/mL. This risk appeared greater when using a positive-negative dnDSA MFI cutoff of >1000 (TAC C 0 6-7.9 ng/mL: OR 2.60 95% CI 1.19-5.71, P = .017; 4-5.9 ng/mL: OR 7.09 95% CI 2.88-17.40, P < 0001; 0-3.9 ng/mL: OR 7.63 95% CI 1.61-36.11, P = .010). Lower mean TAC ranges were also associated with more rejection by 12 months and death-censored graft survival by 5 years, as shown in Table 2 . Kaplan-Meier plots for time to dnDSA, acute rejection, and death-censored graft loss are shown in Figure 2 . Estimates of dnDSA-free survival obtained using the interval censored nonparametric method were similar to results obtained by the log rank test.
| Tacrolimus time in therapeutic range
Using a therapeutic range of 5-10 ng/mL, 150 patients (27.9%) had a TTR <60% and 255 (47.4%) patients a TTR <75% by 12 months. and survival to dnDSA, acute rejection, and death-censored graft loss are shown in Figure 3 . is likely one of the most important modifiable factors in preventing dnDSA and its sequela. In the present study, we attempted to more clearly delineate therapeutic goals that may be utilized in a clinical setting to minimize the risk of dnDSA formation in kidney transplant recipients. We have shown overall lower TAC exposure to be associated with a risk of dnDSA and that this risk increases in a uniform and graded fashion with decreasing TAC levels. Moreover, we have illustrated that even when a therapeutic range is established, it is often difficult to keep patients within target trough concentrations. More than a quarter of our patients were in a therapeutic range of 5-10 ng/ mL less than 60% of the time, which was not only associated with increasing rates of dnDSA but also acute rejection and graft loss.
There are few data available on the influence of immunosuppression on dnDSA formation, and most of these reports compare drugs rather than evaluate dosing of a specific drug. 8, 29 Optimal therapeutic dose and the risk of dnDSA may be particularly important in the setting of TAC therapy, where concerns about calcineurin-inhibitor toxicity have prompted attempts with its withdrawal or minimization. In the CTOT-09 study, 14 of 21 immunologically low-risk patients were randomized to TAC withdrawal before the study was terminated due to high rates of acute rejection and 5 patients developing dnDSA. In this study, lower mean TAC C 0 in the first year was incrementally associated with worsening death-censored graft survival by 5 years.
We also found that lower mean TAC C 0 was associated with an increased risk of acute rejection. In the Elite-Symphony study, the low-dose TAC group achieved a mean TAC C 0 of 6.4 ng/mL in the first year after transplantation, and there was an overall low incidence of T cell-mediated acute rejection of 12.3%. Consistent with Eckberg et al, our patients had a mean TAC C 0 of 7.1 ng/mL in the first year after transplantation, with a low incidence of T cell-mediated rejection of 9.1%. However, when we delineated mean TAC C 0 into different ranges, we found that patients with a mean TAC C 0 of 0-3.9 ng/mL and 4-5.9 ng/mL had a higher risk of T cell-mediated rejection compared to patients with a mean TAC C 0 of ≥8 mg/mL. This finding may be supported by other retrospective reports 32 as well as Gatault et al, as their control group achieved a TAC C 0 of 7.4 ng/mL with 3 episodes of T cell-mediated rejection at 12 months and the intervention group achieved a TAC C 0 of 5.6 ng/mL with 11 episodes of rejection (P = .016) at 12 months.
In addition, there is very little information to guide therapeutic monitoring of TAC in relation to dnDSA. High intrapatient variability of TAC levels, often expressed as standard deviations or coefficients of variation, have been associated with increased risk of dnDSA, acute rejection, and graft loss in kidney recipients. [19] [20] [21] [22] In a retrospective study of TAC levels in 310 patients, Rodrigo et al found that more than one third of their patients had a coefficient of variation above 30% and more than one half of all patients with dnDSA had a coefficient of variation greater than 30% (HR 2.925, P = .002). 20 Vanhove et al analyzed TAC levels in relation to protocol biopsy at 3 months and 2 years in 220 recipients, finding that higher intrapatient variability of TAC correlated with worsening chronic histologic lesions. 33 The authors hypothesized that these patients experienced alternating periods of underexposure (alloimmune injury) and overexposure (calcineurin-inhibitor nephrotoxicity).
Although these data suggest an important proof of concept, the realtime clinical utility is limited as coefficients of variation are generally not computed at the bedside, nor are clinical decisions based on the result.
Warfarin and TAC share a high degree of inter-and intrapatient variability confined within a narrow therapeutic window. TTR is a validated method for assessing effective warfarin therapy and has been used as a means to risk stratify patients, 24 evaluate the effectiveness of dosing protocols at individual centers for quality improvement, 34 to compare the effectiveness of therapy among centers, 35, 36 and as a standard when comparing the efficacy of warfarin therapy to direct oral anticoagulants in large clinical trials. 37 We applied TTR to our cohort and found that a significant portion of our patients were out of our defined therapeutic range. Moreover, patients who had a TTR of <60% had a 2-fold risk of dnDSA and 4-fold risk of acute rejection at 12 months, whereas having TTR <60% in the first year was associated with a 3-fold risk of graft loss by 5 years. Although the outcomes analyzed in this study are related specifically to risks associated with time below therapeutic range, time in therapeutic range may be better suited to capture several risks that might be synergistic, including underexposure and alloimmune injury, overexposure and the risk of associated toxicities, and the variability that often exists in-between.
This study has several notable limitations. Mean TAC trough concentrations obscure intrapatient variation, which places patients at increased risk for dnDSA. Although significant effort was devoted to chart review to ensure accurate inpatient and outpatient TAC measurements, some TAC levels may not represent true troughs. We chose to include inpatient TAC levels because it more closely mirrors clinical practice when calculating TTR; however, these levels may be affected by concurrent illness and medications during hospitalizations. DSA was also typically measured at discrete time points, and some TAC levels may have been included in the analysis after the development but before the detection of antibodies. However, our interval censored analysis of time to dnDSA did not show any discrepancies with respect to the impact of mean TAC C 0 on the development of dnDSA. We also use an MFI cutoff of >500 for positive dnDSA, which may appear different compared to other labs. Our positive-negative MFI cutoff is normalized against a negative control bead, is at least 2 standard deviations above the mean of the negative control serum, and our lab has been in consensus for all antibody detections in proficiency testing. Moreover, we
found similar results when we performed our analysis using a positivenegative dnDSA MFI cutoff of >1000. In addition, the retrospective nature of this study introduces the possibility of important confounders that may have influenced TAC dosing and the risk of adverse outcomes, thereby limiting the ability to draw conclusions about cause and effect.
Finally, this analysis was not performed in subgroups of patients who may be at lower risk of immunologic injury and/or higher risk of infectious or malignancy complications, thereby requiring lower TAC dosing.
In summary, there are few data to help guide optimal dosing of our most commonly used maintenance immunosuppressant to prevent one of our most common reasons for graft loss. We found that overall TAC exposure was associated with dnDSA in the first year after kidney transplantation, with lower levels demonstrating a uniform and graded increase in risk at levels often targeted by transplant centers.
Furthermore, we applied time in therapeutic range to TAC therapy and found that a sizable portion of patients were out of our predefined target range, which was associated with increased risk of dnDSA, acute rejection, and graft lost. TAC time in therapeutic range may be a useful method to identify patients at modifiable risk of adverse outcomes and as a standard to evaluate TAC dosing among centers in both clinical and research settings.
